A study of efficacy and safety of sertraline for the treatment of major depressive disorder patients, who have benn unremitted or intolerant by paroxetine or fluvoxamine

A study of efficacy and safety of sertraline for the treatment of major depressive disorder patients, who have benn unremitted or intolerant by paroxetine or fluvoxamine - Efficacy of sertraline for SSRI non-remitted or intolerant cases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002654

Enrollment

140

Registered

2009-10-26

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

Switching from prior SSRI (fluvoxamine or paroxetine) to sertraline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent by patients 2. more than 19 years old, less than 70 years old 3. Major depessive diorder by DSM-IVTR 4. unremitted or intorelant patients by paroxetine or fluvoxamine

Exclusion criteria

Exclusion criteria: 1. severe physical diseases (heart, liver, kidney) 2. significant risk of suicide 3. under treatment with cognitvie-behavioral therapy of ECT 4. pregnant or breast-feeding women or women, who may be pregnant 5. organic brain disease 6. patients, whom investigaters regard as inapporopriate for subjects

Design outcomes

Primary

Measure	Time frame
remission rate by QIDS-SRJ	—

Secondary

Measure	Time frame
response rate by QIDS-SRJ response rate by HAMD remission rate by HAMD reduction in QIDS-SRJ scores	—

Countries

Japan

Contacts

Public ContactTakeshi Inoue

Hokkaido University Hospital Psychiatry

tinoue@med.hokudai.ac.jp011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026